Compare MIST & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIST | EARN |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3M | 179.2M |
| IPO Year | 2019 | 2012 |
| Metric | MIST | EARN |
|---|---|---|
| Price | $1.30 | $4.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $8.00 | $5.38 |
| AVG Volume (30 Days) | ★ 1.4M | 398.2K |
| Earning Date | 05-13-2026 | 06-16-2026 |
| Dividend Yield | N/A | ★ 20.51% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,915.14 | $7.69 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $4.27 |
| 52 Week High | $3.06 | $6.08 |
| Indicator | MIST | EARN |
|---|---|---|
| Relative Strength Index (RSI) | 29.54 | 46.61 |
| Support Level | $1.00 | $4.50 |
| Resistance Level | $2.30 | $4.77 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 5.88 | 38.66 |
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.